100mg Tirzepatide: Making Sense of the Dose Numbers

You've seen '100mg' listed somewhere online, here's where it comes from

Picture this: you're researching tirzepatide and a product page or forum post mentions 100mg. It sounds plausible because other medicines do come in doses that size, so the number doesn't immediately trigger alarm bells. The reality is that tirzepatide works at a fundamentally different scale. The licensed Mounjaro pen delivers between 2.5mg and 15mg per weekly injection, doses measured carefully to activate GIP and GLP-1 receptors without flooding the system.

The 100mg figure turns up in a handful of places: early-phase pharmacology studies testing dose-response curves in lab settings, compounded peptide products sold in grey markets (often as a lyophilised powder requiring reconstitution), and occasionally as a mis-stated cumulative figure from someone who has added up weeks of treatment. None of these translate into a licensed product you would receive from a GPhC-registered UK pharmacy. The tirzepatide overview on this site covers the licensed dose range in full if you want the detail.

One misconception worth letting go gently: some people assume that a higher milligram number always means a stronger or more effective product. With tirzepatide, the therapeutic ceiling established in clinical trials was 15mg weekly. Going beyond the licensed range does not improve results; it simply moves outside the evidence base entirely.

The six licensed strengths and what each one is actually for

Tirzepatide as prescribed through any legitimate UK route comes in exactly six strengths. The 2.5mg pen is where everyone begins, and its purpose is settling the body into the medicine rather than producing immediate weight loss, nausea and digestive discomfort are most common in the early weeks, and the low starting dose keeps them manageable. From there the prescriber typically steps up through 5mg, 7.5mg, 10mg, 12.5mg equivalent milestones and 15mg, pausing at each level for around four weeks.

The NHS tirzepatide patient page confirms this titration schedule and describes what to expect at each stage, which is a useful companion to any prescriber's guidance. Not everyone reaches 15mg; the right maintenance dose is the highest one a person tolerates well and responds to, a decision made between the patient and their prescriber over time, not at the outset. A look at what the 30mg reference means in the context of total monthly supply helps clarify another common point of confusion about how the pens are packaged and counted.

Each pen contains four doses, so a single pen covers one month of treatment at any given strength. That packaging detail is sometimes misread as the dose itself, another reason the numbers can seem puzzling at first glance.

What the clinical trial evidence says about effective doses

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled thousands of adults with obesity and measured outcomes across the full dose range. At the 15mg dose over 72 weeks, participants saw an average body-weight reduction of around 20–21%. Lower maintenance doses produced meaningful results too, though the average loss was smaller. The trial design is described on the NICE technology appraisal TA1026 page, which is also the document underpinning the NHS rollout criteria.

None of the SURMOUNT programme trials tested doses above 15mg in adults seeking weight management. The evidence base that led to UK licensing (and to NICE's recommendation for adults with a BMI of 35 or above alongside at least one weight-related condition) was built entirely within the 2.5mg to 15mg range. Doses outside that range, including any product described as 100mg tirzepatide, fall outside the scope of that evidence. They also fall outside the scope of what a GPhC-registered prescriber can lawfully issue a prescription for in the UK.

Clinical trials for new formulations (including longer-acting or depot-style versions of GLP-1 and GIP medicines) do explore higher total drug loads in early phases. That research context is where large milligram figures sometimes leak into public conversation. Interesting science, but firmly at the research stage.

How a legitimate UK prescription for tirzepatide actually works

Tirzepatide is a Prescription-Only Medicine in the UK, which means a qualified prescriber must assess your suitability before any supply. That assessment covers your current health, other medicines you take, relevant conditions, and your goals. At nume, a GPhC-registered Independent Prescriber reviews every consultation personally, the same day it arrives.

The cost of tirzepatide through private providers has changed since Eli Lilly adjusted UK list pricing; the context behind that shift is worth reading if cost is a factor in your thinking, and our overview of the Mounjaro price increase covers it plainly. For anyone considering whether treatment is right for them, the starting point is always a clinical conversation, not a dose comparison. You can explore the weight-loss treatment options available through a regulated pharmacy, and if tirzepatide seems like it might suit your situation, check your eligibility with our prescribers.